Evidence map›Paper›PMID 37374339›Full record

ReviewMedicina (Kaunas, Lithuania)2023

GAD65 Antibody-Associated Epilepsy.

Justina Valinčiūtė, Neringa Jucevičiūtė, Renata Balnytė, Giedrė Jurkevičienė, Giedrė Gelžinienė

Open access · goldAbstract readReviewCase Reports
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Type 1 diabetes and the risk of epilepsy: A meta-analysis.Journal of diabetes investigation · 2024
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Epilepsia Partialis Continua in an Adolescent: A Case of Diagnostic Overshadowing.Journal of investigative medicine high impact case reports
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Justina ValinčiūtėFaculty of Medicine, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Neringa JucevičiūtėDepartment of Neurology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Renata BalnytėDepartment of Neurology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Giedrė JurkevičienėDepartment of Neurology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Giedrė GelžinienėDepartment of Neurology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
Lithuanian University of Health Sciences · LT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune processes are an increasingly recognized cause of seizures. Antibodies against neuronal surface antigens are implicated in the development of acute symptomatic seizures secondary to autoimmune encephalitis, whereas antibodies against intracellular antigens (anti-glutamic acid decarboxylase (GAD) and onconeural antibodies) are found in cases of autoimmune-associated epilepsy (AAE). AAE is described as isolated drug-resistant epilepsy without any specific magnetic resonance imaging (MRI) or cerebrospinal fluid changes and with a very limited response to immunotherapy. We present a clinical case and a literature review on autoimmune-associated epilepsy to increase awareness of this disease and illustrate its complexity. This is a clinical case of a female with a history of refractory focal epilepsy. The patient had been given several trials of multiple antiepileptic drugs and their combinations without any clear effect. Multiple evaluations including brain MRI, PET, and interictal and ictal electroencephalograms were performed. An APE2 score was calculated with a result of 4 and, in the presence of anti-GAD65 antibodies in the serum, the diagnosis of AAE was confirmed. There was no effect after five sessions of plasma exchange; however, after a course of intravenous immunoglobulin, a positive but temporary clinical effect was noticed: anti-GAD65 levels initially decreased but rebounded to previous levels 6 months later.

Indexed as

Drug Resistant EpilepsyEncephalitisEpilepsyAntibodiesAutoantibodiesBrainFemaleHumansSeizuresAntibodiesAutoantibodiesautoimmune encephalitisautoimmune epilepsyglutamic acid decarboxylase (GAD)seizures

Identifiers

PMID37374339
PMCPMC10305176
OpenAlexW4380628977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.